Clinical trials: Human Immunodeficiency Virus Exposure
Contact With or Exposure to Human Immunodeficiency Virus
ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention
The goal of this study is to learn how well long-acting lenacapavir works to prevent human immunodeficiency virus (HIV) infection in people at higher risk of getting HIV in Brazil.
- Trial name
- ImPrEP LEN (NCT07497594)
- Testing
- Lenacapavir long-acting, Tenofovi-Emtricitabine (TDF/FTC) tablet
- Where
- 8 sites in Brazil
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Oswaldo Cruz Foundation
HIV Infections
The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir
Although CAB LA PrEP has been proven efficacious in blinded randomized controlled clinical trials, additional research is needed to evaluate effectiveness in real world settings as well as to identify effective implementation…
- Trial name
- ImPrepCab (NCT05515770)
- Testing
- Cabotegravir Injection
- Where
- Brazil
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Evandro Chagas National Institute of Infectious Disease
HIV Preexposure Prophylaxis
The SwissPrEPared Study
Nested within the SwissPrEPared Program, the "SwissPrEPared Study" - a large, multicentric, nation-wide cohort study - aims to longitudinally follow individuals asking for PrEP prescription over a period of 3 years.
- Trial name
- NCT03893188
- Where
- 41 sites in Switzerland
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- University of Zurich
HIV, HIV Infections
A Study to Examine the Human Papillomavirus Types Exposure in Women From Southern Africa and Brasil
This is a study to determine what Human Papillomavirus HIV seropositive women in Botswana, South Africa and Brasil have been exposed to during their life. The Human Papillomavirus causes cervical cancer.
- Trial name
- NCT00840905
- Where
- 3 sites in Botswana, Brazil and 1 more
- Volunteers
- 487 people
- Sponsor
- Cynthia S Firnhaber
Pre-Exposure Prophylaxis (PrEP)
eSTEP: An Integrated mHealth Intervention to Engage High-risk Individuals Along the Full PrEP Care Continuum
The long-term goal of this research is to develop a theoretically grounded, effective, accessible and sustainable mHealth PrEP care continuum intervention for men who have sex with men (MSM) and transgender women (TW).
- Trial name
- eSTEP (NCT06159582)
- Testing
- eSTEP, Usual Care
- Where
- United States
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- San Diego State University
HIV Infections, Pregnancy
The Safety and Effectiveness of Zidovudine in HIV-Infected Pregnant Women and Their Infants
To determine whether the rate of HIV transmission from mother to infant can be reduced by continuous oral zidovudine (AZT) treatment to HIV infected pregnant women, intravenous AZT during childbirth, and oral AZT treatment of the…
- Trial name
- NCT00000960
- Testing
- Zidovudine
- Where
- 62 sites in United States, Puerto Rico
- Volunteers
- 1,496 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS, Gender
Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study
To address the critical scientific gaps in PrEP safety for transgender youth and to plan for appropriate implementation of PrEP in transgender youth communities, the study will be conducted in 3 integrated phases.
- Conditions
- HIV/AIDS, Gender, Behavior and Behavior Mechanisms
- Trial name
- NCT03652623
- Testing
- TDF/FTC
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Hektoen Institute for Medical Research
HIV
Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
This study will evaluate the safety and tolerability of the combination of truvada and raltegravir given for 28 days for the prevention of HIV infection.
- Trial name
- NCT01214759
- Testing
- Truvada, Raltegravir
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- The University of Texas Health Science Center, Houston
Pre-Exposure Prophylaxis (PrEP)
Impact of Nursing Involvement on Implementation of HIV Prevention Services
Women comprise 20% of new Human Immunodeficiency Virus (HIV) diagnoses in the United States (U.S.) with 86% attributed to heterosexual contact.
- Trial name
- PrEP-RN (NCT05095818)
- Testing
- PrEP-RN
- Where
- United States
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
HIV Infection, Sexually Transmitted Infection
Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy
Individual-Level Randomized Controlled Trial of an Integrated Strategy of HIV pre-exposure prophylaxis (PrEP) and sexually transmitted infection (STI) post-exposure prophylaxis (PEP) for Young Men
- Trial name
- NCT07658976
- Testing
- HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA, STI PEP - Doxycycline as Doxy-PEP, 3P mHealth package
- Where
- 5 sites in United States, Argentina and 2 more
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- HIV Prevention Trials Network
HIV Infections
Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection
The objective are to assess the nature and incidence of drug intolerance observed with a new antiretroviral triple therapy, Truvada® [0-0-1] + Isentress® 400 mg tablets [1-0-1], prescribed in a setting of the treatment of…
- Trial name
- NCT01114425
- Testing
- raltegravir (Isentress), Truvada®
- Where
- France
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux
Antivirals/HIV
Drug Interaction Study
The purpose of this study is to evaluate the exposure of rifabutin (RIB) when administered with atazanavir and ritonavir (ATV/RTV)
- Trial name
- NCT00646776
- Testing
- Rifabutin, Rifabutin + Atazanavir + Ritonavir
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HIV Infections, HIV Seronegativity
Long-Term Effects of HIV Exposure and Infection in Children
As new drugs and vaccines are developed to prevent HIV disease progression and prolong survival of HIV infected patients, the short-term safety and effectiveness of these treatments are evaluated in research studies.
- Trial name
- NCT00006304
- Where
- 92 sites in United States, Puerto Rico
- Volunteers
- 4,150 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
The Women TDF-FTC Benchmark Study
The study seeks to define the expected blood levels of pre-exposure prophylaxis (PrEP) medications (tenofovir) for cisgender women taking directly observed oral PrEP therapy to understand the frequency of PrEP dosing associated…
- Trial name
- NCT05057858
- Testing
- co-formulated 300 mg TDF/ 200mg FTC
- Where
- Kenya
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Washington
HIV Prevention
Are Louisiana Pharmacists PrEPared? Implementing Training and an Active PrEP (Pre-Exposure Prophylaxis) Prescribing Surveillance Program
Though broadening PrEP (Pre-Exposure Prophylaxis) availability to Louisiana pharmacies addresses key access issues for Louisiana's population, there is no current baseline data which explore current pharmacist and pharmacies'…
- Trial name
- NCT06530225
- Testing
- Education and Mentoring for Prescribing Pharmacists
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Xavier University of Louisiana.
HIV, Human Immunodeficiency Virus
PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5
Canada continues to see an unrelenting stream of new HIV diagnoses, with a disproportionate burden among gay, bisexual, and other MSM in major centers such as Toronto.
- Trial name
- PREP-5 (NCT02149888)
- Testing
- Tenofovir/emtricitabine
- Where
- Canada
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
HIV Infections
HIV Pre-exposure Prophylaxis Implementation Hong Kong Study
While pre-exposure prophylaxis (PrEP) is widely recommended and a number of pilot studies are on-going worldwide, progress of its implementation in the real world setting has been slow, especially in Asia.
- Trial name
- NCT04367688
- Testing
- Tenofovir Disoproxil Fumarate 300 mg / emtricitabine 200 mg
- Where
- Hong Kong
- Volunteers
- 339 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
HIV Prevention
Evaluation of PrEP-30: a Demonstration Project of Pre-exposure Prophylaxis for MSM and Other High-risk Group Clients at the Thai Red Cross Anonymous Clinic
PrEP-30 is a demonstration project to assess the feasibility of providing oral PrEP to MSM and other individuals at-risk for HIV in Bangkok, Thailand as a service that is funded entirely through user fees.
- Trial name
- PrEP-30 (NCT02437981)
- Testing
- PrEP
- Where
- Thailand
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Thai Red Cross AIDS Research Centre
Adherence, Medication, Risk Behavior
DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence
The researchers are working with a technology company, AiCure, to develop a smartphone app, DOT Diary, which combines two drug adherence strategies.
- Conditions
- Adherence, Medication, Risk Behavior, Pre-Exposure Prophylaxis, HIV Prevention
- Trial name
- NCT03387462
- Testing
- Emtricitabine / Tenofovir Disoproxil Oral Tablet, DOT Diary mobile app
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Public Health Foundation Enterprises, Inc.
HIV Infections
HIV Non Occupational Post-Exposure Prophylaxis (PEP)
This study will evaluate how safe and tolerable a combination of taking three-drugs will be for the purpose of preventing HIV transmission after a high-risk sexual contact exposure in HIV uninfected adults.
- Trial name
- NCT00594646
- Testing
- TRUVADA + Raltegravir
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Fenway Community Health